Filing Analysis
Tempest Therapeutics is addressing a Nasdaq non-compliance notice regarding board vacancies by appointing two new directors and a new Principal Financial Officer following the resignation of its CFO.
🚩 Red Flags
- Nasdaq non-compliance notice: The company was notified on May 22, 2026, that it was no longer in compliance with Listing Rules 5605(b)(1)(A) and 5605(c)(4).
- CFO Departure: The resignation of the CFO (Nicholas Maestas) coincides with the board reconstitution and delisting risk.
- Multiple 8-K items: The filing covers officer departures, director appointments, and regulatory compliance issues (Items 5.02 and 7.01).
- Board instability: The company admits to having more than one vacancy on its board and committees, leading to the Nasdaq notice.
📋 Key Facts
- CFO Nicholas Maestas resigned effective June 5, 2026.
- Justin Trojanowski appointed as VP Finance, Principal Financial Officer, and Corporate Secretary effective June 5, 2026.
- Dr. John David Yee and Mr. William Drake Richey appointed as Class II directors effective June 4, 2026.
- Nasdaq notified the company on May 22, 2026, that it was out of compliance due to multiple board and committee vacancies.
- The company has reduced annual cash retainers for non-employee directors (e.g., base retainer now $20,000).
- New directors will receive initial option awards of 25,000 shares each.
Tempest Therapeutics entered into an inducement agreement on May 28, 2026, to encourage a warrant holder to exercise existing warrants at a significantly reduced price. The company raised approximately $2.0 million in gross proceeds but issued substantial new warrants as a sweetener.
🚩 Red Flags
- Significant dilution: The company issued new warrants for double the amount of shares exercised (2.34M new warrants vs 1.17M shares exercised).
- Price reduction: The exercise price was slashed by over 50% (from $3.50 to $1.73) to induce the cash infusion, signaling desperation for liquidity.
- High cost of capital: The use of a placement agent with both warrant and cash fee components increases the overall cost of this small capital raise.
📋 Key Facts
- Existing warrants originally issued in Nov 2025 with a $3.50 exercise price were induced to be exercised at a reduced price of $1.73 per share.
- The holder exercised warrants for 1,172,414 shares of common stock.
- In exchange, the company issued a 'New Warrant' to purchase up to 2,344,828 shares at $1.73 per share, expiring May 29, 2028.
- Gross proceeds from the transaction were approximately $2.0 million.
- H.C. Wainwright & Co., LLC acted as placement agent and received warrants for 82,069 shares at $2.1625 per share, plus a 7% cash fee on future New Warrant exercises.
Tempest Therapeutics reported the resignation of Ms. Simantov from its Board of Directors effective May 23, 2026. The departure includes a Separation Agreement where the director waived accrued and unpaid retainer fees.
📋 Key Facts
- Ms. Simantov resigned from the Board of Directors on May 23, 2026.
- The company stated the resignation was not the result of any disagreement regarding operations, policies, or practices.
- A Separation Agreement was executed involving the waiver of all accrued and unpaid retainer fees by Ms. Simantov.
- Existing stock option awards and capital stock ownership remain unaffected.
- Indemnification rights remain in effect for six years following the separation.
Tempest Therapeutics (TPST) received a Nasdaq deficiency letter on May 19, 2026 for failing to meet the minimum stockholders' equity requirement of $2,500,000, reporting only $822,000 as of March 31, 2026. Compounding the crisis, two independent directors resigned simultaneously (Michael Raab and Christine Pellizzari), triggering non-compliance across four additional Nasdaq governance rules. The Company has until July 6, 2026 to submit a compliance plan, with a potential 180-day extension if accepted.
🚩 Red Flags
- Stockholders' equity of $822,000 is only 32.9% of the required $2,500,000 Nasdaq minimum — a deep and severe shortfall
- Company fails ALL three alternative continued listing standards simultaneously (no path to easy cure)
- Two independent directors resigned simultaneously, triggering non-compliance across FOUR separate Nasdaq governance rules at once
- Ineligible for standard cure period due to multiple simultaneous board/committee vacancies — forced into formal compliance plan process
- Forward-looking statements explicitly cite need to 'continue to operate as a going concern,' signaling acute liquidity distress
- Forward-looking statements also cite 'current liquidity position and the need to obtain additional financing to support ongoing operations'
- Multiple 8-K items triggered in a single filing period (Item 3.01 delisting + Item 5.02 officer/director departures)
- Biotech clinical-stage company with severely depleted equity — high dilution risk if equity raise attempted to regain compliance
- No assurance language: 'there can be no assurance that the Panel will grant the Company's request for continued listing'
📋 Key Facts
- Nasdaq deficiency letter received May 19, 2026 for violation of Listing Rule 5550(b)(1) (minimum stockholders' equity of $2,500,000)
- Reported stockholders' equity of only $822,000 as of March 31, 2026 — a shortfall of approximately $1,678,000
- Company also fails all three alternative continued listing standards: no market value of listed securities ≥$35M, no net income ≥$500K in most recent or two of last three fiscal years
- Directors Michael Raab and Christine Pellizzari resigned, disclosed in a separate May 22, 2026 Form 8-K (Item 5.02)
- Board independence non-compliance triggered under Nasdaq Listing Rule 5605(b)(1) (majority independent directors)
- Audit Committee non-compliance under Nasdaq Listing Rule 5605(c)(2)(A) (requires at least 3 independent members)
- Compensation Committee non-compliance under Nasdaq Listing Rule 5605(d)(2)(A) (requires at least 2 independent members)
- Nominating and Corporate Governance Committee non-compliance under Nasdaq Listing Rule 5605(e)(1)
- Company is NOT eligible for the standard cure period because there is more than one vacancy across all committees
- Compliance Plan deadline: July 6, 2026 (45 calendar days from May 19, 2026)
- If Compliance Plan accepted, up to 180-day extension may be granted to regain compliance
- Forward-looking statements explicitly reference 'need to continue to operate as a going concern'
- Filing signed by CFO Nicholas Maestas on May 22, 2026
Tempest Therapeutics, Inc. (TPST) filed an 8-K on May 22, 2026 disclosing the simultaneous resignation of three board members — Stephen Brady, Michael Raab, and Christine Pellizzari — all effective the same day. Each resigning director entered into a Separation Agreement waiving all accrued and unpaid retainer fees. The mass departure of three directors in a single event is a significant governance red flag for a micro-cap clinical-stage therapeutics company.
🚩 Red Flags
- Simultaneous resignation of three board members on the same day is highly unusual and raises serious governance concerns, even if the boilerplate 'no disagreement' language is included.
- Mass board departure at a micro-cap clinical-stage biotech could signal strategic uncertainty, disagreement over company direction, or impending major transaction.
- Directors waiving accrued and unpaid retainer fees is atypical and may suggest financial distress or a negotiated exit under pressure.
- Reference to a previously filed 10-K/A (March 30, 2026) suggests the company has had prior financial reporting amendments, adding to governance concerns.
- No replacement directors announced in the same filing, raising questions about board continuity and governance adequacy.
- Separation Agreements details deferred to a future 10-Q filing, limiting immediate transparency.
📋 Key Facts
- Three board directors resigned simultaneously on May 22, 2026: Stephen Brady, Michael Raab, and Christine Pellizzari.
- All resignations were effective immediately on the date of notification (May 22, 2026).
- Each director executed a Separation Agreement waiving all accrued and unpaid retainer fees under the non-employee director compensation program.
- The Company stated it was not informed that the resignations resulted from any disagreement with the Company on operations, policies, or practices (per Item 5.02(a)(1) boilerplate).
- Existing stock option awards and share ownership rights of the departing directors are unaffected by the Separation Agreements.
- Indemnification agreements for each departing director remain in full force for six years from separation.
- Full text of Separation Agreements will be filed as exhibits to the 10-Q for the quarter ended June 30, 2026.
- The filing was signed by Matthew Angel, President and CEO.
- The Company references a previously filed 10-K/A (March 30, 2026), suggesting a prior restatement or amendment activity.
Tempest Therapeutics, Inc. reported its financial results for the first quarter ended March 31, 2026. The filing serves as a standard quarterly update to investors regarding the company's financial condition and business highlights.
📋 Key Facts
- The filing was made on May 14, 2026, reporting on the quarter ended March 31, 2026.
- The information was furnished under Item 2.02 (Results of Operations and Financial Condition).
- The company included a press release as Exhibit 99.1 detailing financial performance and business updates.
Tempest Therapeutics issued a clinical update at the ISCT 2026 Annual Meeting and updated its corporate presentation for investors.
📋 Key Facts
- Company issued a press release titled 'Tempest Presents Clinical Update at ISCT 2026 Annual Meeting' on May 6, 2026.
- An updated corporate presentation dated May 2026 was posted to the company's website.
- The clinical update was presented at the International Society for Cell & Gene Therapy (ISCT) 2026 Annual Meeting.
Tempest Therapeutics announced its financial results for the fiscal year ended December 31, 2025, and provided business highlights. The disclosure was made via a press release furnished to the SEC on March 30, 2026.
📋 Key Facts
- Announced financial results for the fiscal year ended December 31, 2025
- Press release issued and dated March 30, 2026
- Information furnished under Item 2.02 regarding results of operations and financial condition
Tempest Therapeutics entered into a $2.0 million private placement (PIPE) involving common stock, pre-funded warrants, and two series of common warrants with institutional and strategic investors. The deal includes participation from Factor Bioscience Inc. and requires stockholder approval for the full exercise of the issued warrants.
🚩 Red Flags
- Small raise size ($2M) relative to typical biotech burn rates may indicate urgent liquidity needs.
- High warrant coverage: The deal includes nearly 2 million warrants for a ~925k share/pre-funded warrant base, which is highly dilutive.
- The requirement for stockholder approval for warrant exercise adds execution risk and potential for future non-compliance.
📋 Key Facts
- The company raised approximately $2.0 million in gross proceeds through the sale of 462,964 shares and 462,963 pre-funded warrants.
- The combined purchase price per share/unit was $2.16.
- The offering includes Series A and Series B warrants for an aggregate of 1,851,854 additional shares of common stock.
- Factor Bioscience Inc. participated as a 'Strategic Investor' in the placement.
- The company must seek stockholder approval for the issuance of shares upon exercise of the Common Warrants within 90 days.
- H.C. Wainwright & Co. acted as the placement agent, receiving fees of 3-6% of gross proceeds.
- Registration rights agreement requires a resale registration statement to be filed within 15 days of the agreement.
Tempest Therapeutics announced interim results from its ongoing REDEEM-1 trial of TPST-2003 and updated its corporate presentation. The company is currently preparing for a potential U.S. registrational study for the candidate in 2026.
📋 Key Facts
- Interim results released for the REDEEM-1 trial evaluating TPST-2003 on February 25, 2026
- Company is preparing for a potential U.S. registrational study in 2026
- Updated corporate presentation dated February 25, 2026, was posted to the company website
- The filing includes Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events)